Product Platform Overview

Our product platform is based on utilizing a gasotransmitter to up-regulate the heme-oxygenase enzyme for therapeutic purposes. The heme oxygenase enzymes and their metabolites have been shown to exhibit therapeutic properties, including anti-inflammatory and anti-apoptotic properties in neural injury including cerebral injury, sickle cell disease and kidney transplant, as well as anti-sickling properties specific to sickle cell disease. Hillhurst has developed the ability to formulate its lead drug product for both oral and intravenous dosing, overcoming a key barrier that has prevented the development of this gasotransmitter for therapeutic use.